How should randomized controlled trials in epithelial ovarian cancer be interpreted?

Affiliations

¹ Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
² Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy anna.fagotti@policlinicogemelli.it.

Free article

Comment

Inge Peters et al. Int J Gynecol Cancer. 2022.

Free article

. 2022 May 3;32(5):693.

doi: 10.1136/ijgc-2022-003541.

¹ Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
² Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy anna.fagotti@policlinicogemelli.it.

No abstract available

Keywords: Ovarian Cancer.

Conflict of interest statement

Competing interests: None declared.

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. Harter P, et al. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294. N Engl J Med. 2021. PMID: 34874631 Clinical Trial.